Individual Differences in Neurobehavioral Effects of Pyridostigmine
Abstract
We conducted two double-blind studies designed to test the following specific hypotheses about pyridostigmine bromide (PB): (a) under well-controlled conditions, AChE and/or BuChE inhibition will be related to alterations in the performance of complex tasks, heart rate variability (HRV), and peripherally mediated measures of physiological and sensorimotor functions; (b) individual differences can be differentiated from pharmacokinetic variability by use of a dose-response design, and (c) PB will produce more centrally-mediated effects under heat stress. Both studies were double-blind, placebo-controlled, crossover design. Volunteers were 18-35 yrs of age. In Study 1, physiological, sensorimotor, and cognitive measures were collected. In addition, plasma and urinary PB and 3-hydroxy-N-methylpyridinium bromide (THMP, the major metabolite of PB), as well as AChE and BuChE, were measured. These endpoints were measured, time- locked to time of intake of the pills and time of the test battery. Significant PB effects on heart rate and heart rate variability were observed. In study 2, volunteers were exposed to heat prior to and during testing; on the other day, they were tested at normal room temperature. Study 1 findings on side effects, heart rate and heart rate variability were replicated.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2001
- Accession Number
- ADA393449
Entities
People
- Mary R. Cook
Organizations
- MRIGlobal